Every material Form 8-K UTAH MEDICAL PRODUCTS INC has filed with the SEC since August 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Utah Medical Products said its Board approved a quarterly cash dividend of $.315 per share, a 1.6% increase over the prior regular quarterly dividend. The dividend is payable January 5, 2027 to shareholders of record at the close of business on December 17, 2026.
Quarterly cash dividend of $.315 per share, up 1.6% from the prior regular quarterly dividend
Record date is December 17, 2026; payment date is January 5, 2027
Announced November 3, 2026 and disclosed in Exhibit 99.1 to the Form 8-K
Utah Medical Products reported third-quarter 2026 revenue of $8.6 million, down 12.1% from $9.8 million a year earlier, as sales to two former major customers ended. Diluted EPS rose 6.8% to $0.876 on lower share count and higher operating income, but nine-month diluted EPS fell 5.3% to $2.537. Management projects a full-year 2026 sales decline of close to 7%, compared with the 12% year-to-date decline through September.
Q3 2026 revenue was $8.6 million, down 12.1% from $9.8 million in Q3 2025; nine-month revenue was $25.9 million, down 12.2%
Q3 2026 net income was $2.8 million, up 5.9%; nine-month net income was $8.1 million, down 7.4%
Management's 2026 full-year sales projection is a decline close to 7%, versus the 12% year-to-date decline
Cash and investments were $85.2 million at September 30, 2026, and the company reported no debt
Utah Medical Products said its subsidiary Femcare Ltd has bought all common shares of Orion Medical Supplies Ltd, a private UK maker and distributor of harm reduction medical devices. The company expects Orion to add about $6 million to its annual consolidated sales, and the purchase was paid from cash reserves.
Femcare Ltd purchased all common shares of Orion Medical Supplies Ltd, announced August 31, 2026
Purchase price was £3.6 million, paid from cash reserves
Orion is expected to add about $6 million to UTMD's current consolidated annual sales
Orion operations will move into Femcare's existing Romsey, UK facilities after a transition period
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every UTAH MEDICAL PRODUCTS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →